8.01
3.49%
0.27
시간 외 거래:
8.04
0.03
+0.37%
전일 마감가:
$7.74
열려 있는:
$7.81
하루 거래량:
1.58M
Relative Volume:
1.18
시가총액:
$1.15B
수익:
$175.51M
순이익/손실:
$-78.02M
주가수익비율:
-15.11
EPS:
-0.53
순현금흐름:
$-34.18M
1주 성능:
-0.74%
1개월 성능:
-16.13%
6개월 성능:
+37.16%
1년 성능:
+1.78%
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
명칭
Aurinia Pharmaceuticals Inc
전화
250-744-2487
주소
#140, 14315 - 118 AVENUE, EDMONTON, BC
AUPH을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
8.01 | 1.15B | 175.51M | -78.02M | -34.18M | -0.53 |
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-11-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2022-05-05 | 재개 | Cantor Fitzgerald | Overweight |
2021-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
2021-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2021-01-25 | 재확인 | H.C. Wainwright | Buy |
2020-11-03 | 재확인 | H.C. Wainwright | Buy |
2020-06-17 | 개시 | BTIG Research | Buy |
2020-05-05 | 개시 | Cowen | Outperform |
2020-01-10 | 개시 | Jefferies | Buy |
2019-12-16 | 재확인 | H.C. Wainwright | Buy |
2018-03-16 | 재확인 | Cantor Fitzgerald | Overweight |
2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
2017-10-30 | 재확인 | H.C. Wainwright | Buy |
2017-05-18 | 재확인 | H.C. Wainwright | Buy |
2017-04-11 | 개시 | Cantor Fitzgerald | Overweight |
2017-03-22 | 재확인 | FBR & Co. | Outperform |
2016-12-30 | 재확인 | H.C. Wainwright | Buy |
2016-08-17 | 재확인 | H.C. Wainwright | Buy |
2016-06-30 | 개시 | H.C. Wainwright | Buy |
2015-05-08 | 개시 | MLV & Co | Buy |
모두보기
Aurinia Pharmaceuticals Inc 주식(AUPH)의 최신 뉴스
(AUPH) Investment Analysis - Stock Traders Daily
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets - MSN
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Aurinia: My 2024 Sell Call Was WrongSo I'm Upgrading To 'Hold' In 2025 (NASDAQ:AUPH) - Seeking Alpha
Nephrotic Syndrome Market Set to Grow Substantially Through 2034, DelveInsight Projects | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squib - The Globe and Mail
Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space? - Inkl
AUPH: Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space? - StockNews.com
Barclays PLC Boosts Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded by StockNews.com to Strong-Buy Rating - MarketBeat
Long Term Trading Analysis for (AUPH) - Stock Traders Daily
New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights - GlobeNewswire Inc.
Aurinia Pharmaceuticals (NASDAQ:AUPH shareholders incur further losses as stock declines 5.2% this week, taking five-year losses to 57% - Simply Wall St
Franklin Resources Inc. Sells 75,024 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Barclays PLC Acquires 143,072 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals laying off dozens in Montgomery County - The Business Journals
State Street Corp Has $21.59 Million Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
(AUPH) On The My Stocks Page - Stock Traders Daily
Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 9.6% - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Charles Schwab Investment Management Inc. Grows Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $10M Stock Buy: Retail Confidence Spikes - MSN
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25% - Simply Wall St
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options - MSN
Aurinia Pharma stock hits 52-week high at $9.76 - Investing.com
Aurinia Pharma stock hits 52-week high at $9.76 By Investing.com - Investing.com UK
Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares - Investing.com India
Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares By Investing.com - Investing.com Australia
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership - Yahoo Finance
We Might See A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Soon - Simply Wall St
PDT Partners LLC Buys 130,204 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Algert Global LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - MSN
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - sharewise
(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat
Aurinia Pharmaceuticals Inc (AUPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):